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Background: The activity of P-glycoprotein (Pgp) and multidrug resistance related protein 1 (MRP1), two
membrane transporters involved in multidrug resistance of colon cancer, is increased by high amounts of
cholesterol in plasma membrane and detergent resistant membranes (DRMs). It has never been investigated
whether omega 3 polyunsatured fatty acids (PUFAs), which modulate cholesterol homeostasis in dyslipidemic
syndromes and have chemopreventive effects in colon cancer, may affect the response to chemotherapy in
multidrug resistant (MDR) tumors.
Methods: We studied the effect of omega 3 PUFAs docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA)
in human chemosensitive colon cancer HT29 cells and in their MDR counterpart, HT29-dx cells.
Results: MDR cells, which overexpressed Pgp and MRP1, had a dysregulated cholesterol metabolism, due to the lower
expression of ubiquitin E3 ligase Trc8: this produced lower ubiquitination rate of 3-hydroxy-3-methylglutaryl-coenzyme
A reductase (HMGCoAR), higher cholesterol synthesis, higher cholesterol content in MDR cells. We found that DHA and
EPA re-activated Trc8 E3 ligase in MDR cells, restored the ubiquitination rate of HMGCoAR to levels comparable with
chemosensitive cells, reduced the cholesterol synthesis and incorporation in DRMs. Omega 3 PUFAs were incorporated
in whole lipids as well as in DRMs of MDR cells, and altered the lipid composition of these compartments. They reduced
the amount of Pgp and MRP1 contained in DRMs, decreased the transporters activity, restored the antitumor effects of
different chemotherapeutic drugs, restored a proper tumor-immune system recognition in response to chemotherapy
in MDR cells.
Conclusions: Our work describes a new biochemical effect of omega 3 PUFAs, which can be useful to overcome
chemoresistance in MDR colon cancer cells.
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Omega 3 polyunsaturated fatty acids (ω3PUFAs), such as
docosahexaenoic acid (DHA) and eicosapentaenoic acid
(EPA), have been reported in the last years to exert signifi-
cant benefits in cardiovascular diseases (where they limit
the formation of atherosclerotic plaque, decrease the pro-
duction of pro-inflammatory cytokines, reduce the recruit-
ment of leukocytes to the arterial wall [1]), inflammatory
diseases and cancer [2]. For instance ω3PUFAs have been
proposed as chemopreventive agents or adjuvant agents in
association with radiotherapy and chemotherapy in specific
tumors [3]. Despite the high number of studies reporting a
significant reduction in the cardiovascular risk for patients
treated with ω3PUFA supplements, some contrasting data
about the benefits of ω3PUFAs in cardiovascular diseases
have emerged recently [4-6]. Also the chemopreventive ef-
fects of ω3PUFAs have been re-discussed in the light of re-
cent experimental works, showing a potential positive
correlation between serum levels of DHA and/or EPA and
increased incidence of prostate cancer [7-10].
Worth of note colon cancer is a diet-related cancer: a
diet rich of saturated fatty acids is an established risk fac-
tor for the onset of colon tumors, whereas ω3PUFA sup-
plementation lowers the incidence of this malignancy [11].
The chemopreventive role of ω3PUFAs in colon cancer is
supported by experimental observations showing that EPA
supplementation reduces the size and number of polyps,
lowers colon cell proliferation, increases apoptosis in mice
harboring APC mutations [12] and in patients with a pre-
vious history of colon adenomas [13]. In vitro studies sug-
gest that the anti-proliferative effect of ω3PUFAs can be
due to increased production of reactive oxygen species
[14], increased DNA strand breaks and cell cycle arrest
[15], and changes in proteins involved in apoptosis, de-
toxification and cell cycle control [16].
One of the most interesting metabolic effects of EPA
and DHA is their positive impact on cholesterol homeo-
stasis: in dyslipidemic rats a diet enriched with PUFAs, in-
cluding ω3PUFAs, favors the reverse cholesterol transport
and increases high density lipoprotein (HDL) cholesterol
[17]; in humans, ω3FA supplementation decreases triglyc-
erides but also increases both HDL and low density
lipoprotein (LDL) cholesterol [18,19]. Only few works
highlighted a direct effect of ω3PUFAs on 3-hydroxy-3-
methylglutaryl-coenzyme A reductase (HMGCoAR), the
enzyme which catalyzes the limiting step of the cholesterol
biosynthesis. In rats, ω3PUFA supplementation prevents
the age-related activation of HMGCoAR in liver, by main-
taining the enzyme constantly phosphorylated on serine
and inhibited [20]. EPA and DHA reduce HMGCoAR ac-
tivity in MCF-7 human breast cancer cells [21]. In colon
cancer cells, the effects of ω3PUFAs are more controver-
sial: for instance, EPA inhibits HMGCoAR activity in
CaCo-2 colon cancer cells [22]; DHA has little effect onthe de novo synthesis of cholesterol in SW620 cells [23],
although it increases the sterol regulatory element binding
protein-2 (SREBP-2), which induces the transcription of
several genes involved in the cholesterol synthesis - e.g.
HMGCoAR and 3-hydroxy-3-methylglutaryl-coenzyme A
synthase (HMGCoAS) [23,24].
We recently showed that a high rate of cholesterol syn-
thesis in colon cancer is critical to produce the phenotype
known as multidrug resistance (MDR), a condition
that makes cells simultaneously unresponsive to different
drugs, unrelated for chemical structure and mechanism of
action [25,26]. One of the main mechanisms of MDR is
the overexpression of membrane ATP binding cassette
(ABC) transporters, such as P-glycoprotein (Pgp/ABCB1),
multidrug resistance related proteins (MRPs/ABCCs),
breast cancer resistance protein (BCRP/ABCG2). By indu-
cing the efflux of chemotherapeutic drugs, ABC trans-
porters limit the intracellular accumulation and toxicity of
several anticancer agents [27]. The activity of Pgp [28] and
BCRP [29,30] is directly related to the amount of choles-
terol in the plasma membrane. Chemoresistant HT29-dx
colon cancer cells have higher levels of HMGCoAR [25]
and greater amounts of membrane cholesterol [25,26]
than chemosensitive HT29 cells. Drugs lowering the
endogenous synthesis of cholesterol – e.g. statins and ami-
nobisphosphonates – decrease Pgp activity [25] and ex-
pression [26] in HT29-dx colon cancer cells, increasing
their chemosensitivity to Pgp substrates. A significant frac-
tion of Pgp, MRP1 and BCRP is embedded in cholesterol-
rich domains of the plasma membrane, such as detergent
resistant membranes (DRMs) [29-31]. Indeed, the onset of
MDR in cancer is paralleled by a progressive enrichment
of cholesterol in DRMs [32].
Of note, ω3PUFAs can be incorporated in plasma mem-
brane [33] and DRMs [34-36], where they increase the
degree of lipid unsaturation, alter the physicochemical
properties of these compartments (e.g. by displacing
cholesterol) and impair the functional activity of several
DRM-associated proteins [34,36,37]. Due to its high poly-
unsaturation and to its longer carbon chain, DHA is poorly
compatible with the ordered cholesterol/glycosphingolipids
disposition in DRMs, and it is a stronger DRM-disrupting
agent than EPA [34].
To our knowledge, there is no information on the effects
exerted by ω3PUFAs on cholesterol metabolism, DRMs
composition, activity of ABC transporters and MDR
phenotype in colon cancer.
In this work we investigated: 1) whether and how
ω3PUFAs modulate the synthesis of cholesterol and the
composition of DRMs in human chemosensitive and che-
moresistant colon cancer cells; 2) whether they impair the
activity of ABC transporters, inducing chemosensitization.
To this aim we treated human chemosensitive colon can-
cer HT29 cells and their resistant counterpart (HT29-dx
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ω3PUFA effects, we compared the effects of EPA and DHA
with those of the omega 6 polyunsaturated fatty acid
(ω6PUFA) arachidonic acid (AA).
Results
ω3PUFAs reduce the de novo cholesterol synthesis in
colon cancer cells
Chemoresistant HT29-dx colon cancer cells exhibited
a significantly higher synthesis of cholesterol when com-
pared to chemosensitive HT29 cells (Figure 1A). The
ω6PUFA AA did not affect the cholesterol synthesis in
both cell lines, except at 200 μM AA; ω3PUFAs DHA and
EPA decreased the cholesterol synthesis starting from
50 μM. Such decrease was more pronounced and statisti-
cally significant in HT29-dx cells (Figure 1A).Figure 1 Effects of ω6PUFAs and ω3PUFAs on cholesterol
synthesis and cells viability in colon cancer cells. HT29 and
HT29-dx cells were incubated for 24 h in the absence (CTRL) or in
the presence of various concentrations (25, 50, 100, 200 μM) of
arachidonic acid (AA), docosahexaenoic acid (DHA), eicosapenta-
enoic acid (EPA) and subjected to the following investigations.
(A) Cells were grown in a medium containing [3H]acetate, then the de
novo synthesis of cholesterol was measured in duplicate as described
in Methods. Data are presented as means ± SD (n = 4). Versus CTRL
HT29 cells: * p < 0.05; versus CTRL HT29-dx cells: ° p < 0.05. (B) Cells
were stained with Neutral Red solution and the absorbance of viable
cells was measured in triplicate spectrophotometrically. Data are
presented as means ± SD (n = 4). Versus respective CTRL: * p < 0.05.All PUFAs reduced the viability of both cell lines at
200 μM (Figure 1B); at 50 μM they did not impair cell via-
bility (Figure 1B), did not induce apoptosis (Additional file
1A) and necrotic/immunogenic death (Additional file 1B).
Since 50 μM PUFA was the lowest concentration able
to decrease the endogenous synthesis of cholesterol in
chemoresistant cells without exerting toxicity per se, it
was chosen for all the subsequent experiments.
ω3PUFAs reduce HMGCoAR expression in colon
chemoresistant cancer cells by increasing its ubiquitination
The higher synthesis of cholesterol in HT29-dx cells was
accompanied by higher enzymatic activity (Figure 2A) and
protein expression (Figure 2B) of HMGCoAR, compared to
HT29 cells. Whereas AA did not modify these parameters,
DHA and EPA significantly lowered the activity (Figure 2A)
and expression (Figure 2B) of HMGCoAR in chemoresis-
tant cells. Interestingly, they had no effect in chemosensi-
tive cells.
HT29-dx cells had higher levels of HMGCoAR
(Figure 3A) and HMGCoAS (Additional file 2A) mRNA
than HT29 cells, and higher nuclear levels of the tran-
scription factor SREBP-2 (Additional file 2B). Neither
ω6PUFA nor ω3PUFAs changed the levels of HMGCoAR
(Figure 3A) and HMGCoAS (Additional file 2A) mRNA,
and the amount of nuclear SREBP-2 (Additional file 2B).
These results suggest that DHA and EPA did not decrease
HMGCoAR expression by down-regulating gene tran-
scription. SREBP-1 was unmodified in each experimental
condition and did not differ between HT29 and HT29-dx
cells (Additional file 2B).
Since HMGCoAR can be negatively regulated at post-
transcriptional level, by phosphorylation on serine [38] or
ubiquitination followed by proteasome degradation [39],
we next investigated whether ω3PUFAs may affect these
events. HMGCoAR was basally phosphorylated on serine
in both HT29 and HT29-dx cells without appreciable dif-
ferences between the two cell populations; PUFAs did not
modify the phosphorylation status (Figure 3B, left panel).
In HT29 cells HMGCoAR was highly ubiquitinated,
both in the absence or presence of PUFAs. By contrast,
the ubiquitination of HMGCoAR was lower in HT29-dx
cells; DHA and EPA, but not AA, restored the ubiquitina-
tion of HMGCoAR to the same level observed in HT29
cells (Figure 3B, left panel). The proteasome inhibitor
MG-132 further increased the amount of ubiquitinated
HMGCoAR, in both HT29 and HT29-dx cells, cultured in
the absence or presence of DHA (Figure 3B, right panel).
These data suggest that the ubiquitination of HMGCoAR
was followed by its degradation via the proteasome
system.
The endoplasmic reticulum (ER) proteins Insig-1 and
Insig-2 are known to mediate the sterol-dependent deg-
radation of HMGCoAR, by recruiting at least two ER-
Figure 2 ω3PUFAs decrease activity and expression of HMGCoAR in chemoresistant colon cancer cells. HT29 and HT29-dx cells were
incubated for 24 h in the absence (CTRL) or in the presence of 50 μM arachidonic acid (AA), docosahexaenoic acid (DHA), eicosapentaenoic acid
(EPA). Simvastatin (1 μM for 24 h, SIM) was chosen as HMGCoAR inhibitor. Cells were lysed and centrifuged to collect the microsomal fraction,
on which the following investigations were performed. (A) HMGCoAR enzymatic activity was measured in duplicate (see Methods). Data are
presented as means ± SD (n = 3). Versus CTRL HT29: * p < 0.02; versus CTRL HT29-dx: ° p < 0.05. (B) Western blotting experiments were performed
using an anti-HMGCoAR antibody; an anti-calreticulin (CRT) antibody was used as a control of equal protein loading. The figure is representative
of three experiments with similar results. The band density ratio between HMGCoAR and CRT was expressed as arbitrary units. Versus CTRL HT29:
* p < 0.05; versus CTRL HT29-dx: ° p < 0.05.
Gelsomino et al. Molecular Cancer 2013, 12:137 Page 4 of 20
http://www.molecular-cancer.com/content/12/1/137associated E3 ligases, namely gp78 and Trc8 [39]. gp78
cooperates with the E2 ubiquitin-conjugating enzyme
Ube2g2 to ubiquitinate HMGCoAR [40]. All these pro-
teins are components of the so-called ER-associated
degradation (ERAD) system, and we investigated whether
they are modulated by ω3PUFAs. To measure the activ-
ity of the ERAD system in cell extracts, microsomal
fractions from HT29 and HT29-dx cells were incubated
with an E1 ubiquitin-activating enzyme, Ube2g2 en-
zyme, ATP and ubiquitin. Then HMGCoAR was iso-
lated by immunoprecipitation and the ubiquitin bound
to HMGCoAR was quantified. As shown in Figure 4A,
HT29-dx cells exhibited a lower ubiquitination of
HMGCoAR, in comparison to HT29 cells. The ubiquiti-
nation was not affected by AA. DHA and EPA instead
increased the amount of ubiquitinated HMGCoAR in
HT29-dx cells to levels comparable to those observed in
HT29 cells.We did not find any difference in the expression of
Insig-1, Insig-2 and gp78 between chemosensitive and
chemoresistant cells, either untreated or treated with
AA, DHA and EPA (Figure 4B). By contrast, Trc8
expression was lower in HT29-dx cells, providing a
putative explanation for the lower ubiquitination of
HMGCoAR in these cells. Since in HT29-dx cells
DHA and EPA did not modify the expression of Trc8
(Figure 4B), but increased the ubiquitination of HMGCoAR
versus the control (Figures 3B and 4A), we next investi-
gated whether these PUFAs directly activate Trc8 enzyme.
In a cell-free system, containing purified HMGCoAR,
recombinant Trc8 and the necessary components
of the ubiquitination machinery, DHA and EPA dose-
dependently increased the ubiquitination of HMGCoAR,
whereas AA was devoid of effects (Figure 4C). On the
other hand, DHA and EPA did not increase the ubiqui-
tination when gp78 replaced Trc8 as E3 ligase
Figure 3 Effects of ω3PUFAs on HMGCoAR transcription, phosphorylation and ubiquitination in colon cancer cells. HT29 and HT29-dx
cells were incubated for 24 h in the absence (CTRL) or in the presence of 50 μM arachidonic acid (AA), docosahexaenoic acid (DHA), eicosapentaenoic
acid (EPA). (A) Total RNA was extracted, reverse-transcribed and subjected to qRT-PCR for HMGCoAR gene. Measurements were performed in triplicate
and data are presented as means ± SD (n = 3). Versus CTRL HT29: * p < 0.005. (B) Cells were subjected to ultracentrifugation to isolate the microsomal
fraction. Left panel: extracts of microsomal fraction were immunoprecipitated with an anti-HMGCoAR antibody, then probed with anti-phosphoserine
(pSer) antibody, anti-ubiquitin antibody or anti-HMGCoAR antibody, to detect the amount of the immunoprecipitated (IP) enzyme. No Ab: extracts in
the absence of the anti-HMGCoAR antibody, a condition used as internal control. Right panel: extracts of microsomal fraction were immunoprecipitated
with an anti-HMGCoAR antibody, then probed with anti-ubiquitin antibody. As a control of proteasome involvement in HMGCoAR degradation, the
proteasome inhibitor MG-132 (10 μM, MG) was added for 16 h, alone or during the last 16 h of the incubation with DHA. The figures are representative
of three experiments with similar results. The 95 kDa band corresponding to native HMGCoAR protein is indicated by the arrow.
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of Trc8.
ω3PUFAs alter the DRMs composition and reduce the
DRM-associated Pgp and MRP1 in chemoresistant colon
cancer cells
Consistently with the higher rate of cholesterol synthesis
(Figure 1A), HT29-dx cells had twice more cholesterol
in whole cell than HT29 cells (Figure 5A). DHA and
EPA decreased cholesterol levels only in HT29-dx cells
(Figure 5A). As expected, DRMs were characterized by a
high cholesterol content in both cell lines (Figure 5B);
again, only in HT29-dx cells DHA and EPA were able to
significantly decrease cholesterol (Figure 5B).
PUFAs were incorporated both in whole cell lipids (Ta-
bles 1 and 2) and DRMs (Tables 3 and 4). Compared to the
other PUFAs, EPA was integrated with higher efficiency in
whole cell lipids in HT29 cells (11.21-fold increase) and
further metabolized to docosapentaenoic acid (DPA); it
was incorporated with a bit lower efficiency in HT29-dx
cells (7.03-fold increase) without any further metabolism
(Tables 1 and 2). DHA showed the same integration effi-
ciency in both cell lines (6.63-fold increase in HT29 cellsand 5.86-fold increase in HT29-dx cells). ω3PUFAs signifi-
cantly reduced the AA whole content in both cell lines.
Both DHA and EPA were integrated in DRM phos-
pholipids even if with lower efficiency compared to their
incorporation in whole cell lipids (Tables 3 and 4); in
particular in HT29-dx cells they were respectively 4.50 ±
1.29% and 3.50 ± 1.20% of total fatty acids (Table 4).
HT29-dx cells had higher amounts of Pgp and MRP1 on
their surface (Figure 5C and Table 5). Interestingly, the de-
crease in cell membrane cholesterol elicited by DHA and
EPA was accompanied by diminished surface levels of Pgp
and MRP1, which became similar to the levels detected in
HT29 cells (Figure 5C and Table 5). In particular, Pgp and
MRP1 were more expressed in DRMs of HT29-dx cells
(Figure 5D) and their DRM-association was significantly
reduced by ω3PUFAs (Figure 5D). AA, which was incor-
porated in whole cell lipids (Tables 1 and 2) and DRMs
(Tables 3 and 4), without changing the amount of choles-
terol (Figure 5A-B), did not modify Pgp and MRP1 levels
(Figure 5C-D; Table 5).
The surface level of BCRP was similar in HT29 and
HT29-dx cells (Figure 5C and Table 5), but the DRM-
associated BCRP was slightly higher in HT29-dx cells
Figure 4 ω3PUFAs increase the ubiquitination of HMGCoAR by activating the E3 ligase Trc8. (A) The microsomal fractions from HT29 and
HT29-dx cells were incubated for 30 min at 37°, without (CTRL) or with 1 μM arachidonic acid (AA), docosahexaenoic acid (DHA), eicosapentaenoic acid
(EPA), in the presence of E1 ubiquitin activating enzyme, E2 ubiquitin conjugating enzyme Ube2g2, ubiquitin and ATP. Samples were immunoprecipi-
tated with an anti-HMGCoAR antibody; ubiquitinated HMGCoAR was measured by a chemiluminescence-based assay. Measurements were performed
in triplicate and data are presented as means ± SD (n = 3). Versus CTRL HT29: * p < 0.005; versus CTRL HT29-dx: * p < 0.005. (B) HT29 and HT29-dx cells
were incubated for 24 h in the absence (CTRL) or presence of 50 μM arachidonic acid (AA), docosahexaenoic acid (DHA) or eicosapentaenoic acid
(EPA), then lysed and centrifuged to collect the microsomal fractions. Western blotting experiments were performed using anti-Insig-1, Insig-2, gp78,
Trc8 antibodies. The expression of calreticulin (CRT) was measured to check the equal protein loading. The figure is representative of three experiments
with similar results. The band density ratio between each protein and CRT was expressed as arbitrary units. Versus CTRL HT29: * p < 0.001. (C) Human
recombinant HMGCoAR was incubated for 30 min at 37°, without (CTRL) or with various concentrations (1 nM, 10 nM, 100 nM, 1 μM) of arachidonic
acid (AA), docosahexaenoic acid (DHA) or eicosapentaenoic acid (EPA), in the presence of E1 ubiquitin activating enzyme, E2 ubiquitin conjugating
enzyme Ube2g2, E3 ligase enzymes gp78 or Trc8. The amount of ubiquitinated HMGCoAR was measured by a chemiluminescence-based assay.
Measurements were performed in triplicate and data are presented as means ± SD (n = 3). Versus CTRL: * p < 0.05.
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DHA and – at lesser extent – AA and EPA increased
the amount of DRM-associated BCRP in both HT29
and HT29-dx cells (Figure 5D). The changes of ABC
transporters on cell surface were not due to differences
in the absolute amount of Pgp, MRP1 and BCRP: all
these proteins were higher in the whole cell lysate of
HT29-dx cells compared to HT29 cells and were not
affected by AA, DHA or EPA (Additional file 3). These
results suggest that the changes of Pgp and MRP1 sur-
face levels are likely due to the redistribution between
plasma membrane and cytosol.ω3PUFAs sensitize multidrug-resistant colon cancer cells
to the antitumor effects of Pgp and MRP1 substrates
The anthracycline doxorubicin, used to generate the re-
sistant HT29-dx cell population [41], is a substrate of
both Pgp and MRP1 [27]. Although anthracyclines are
not used in colon cancer therapy, we chose doxorubicin
as a reliable tool to clarify whether ω3PUFAs chemosen-
sitize resistant cells to anticancer drugs effluxed by Pgp
and MRP1. Doxorubicin was indeed less accumulated in
HT29-dx cells (Figure 6A) and did not reduce their via-
bility (Figure 6B). In correlation with the reduction of
Pgp and MRP1 at cell surface, DHA and EPA increased
Figure 5 Effects of ω3PUFAs on cholesterol and ABC transporters in whole cell and DRMs. HT29 and HT29-dx cells were incubated for
48 h in the absence (CTRL) or in the presence of 50 μM arachidonic acid (AA), docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA). (A) Total
lipids were extracted and the amount of cholesterol was measured in triplicate as reported under Methods. Data are presented as mean ± SD
(n = 3). Versus respective CTRL: * p < 0.01; HT29-dx versus HT29 cells: ° p < 0.01. (B) DRMs were isolated as detergent-resistant membranes by
separation on sucrose gradient; then the amount of cholesterol was measured as reported in Methods. Data are presented as mean ± SD (n = 4).
Versus respective CTRL: * p < 0.05; HT29-dx versus HT29 cells: ° p < 0.01. (C) Surface levels of Pgp, MRP1 and BCRP were measured in
non-permeabilized cells by flow cytometry. The figures shown here are representative of three similar experiments, performed in triplicate. (D)
Western blot detection of Pgp, MRP1 and BCRP on DRM extracts. Flotillin expression was used as control of equal protein loading. The figure is
representative of two experiments with similar results. The band density ratio between each protein and flotillin was expressed as arbitrary units.
Versus CTRL HT29: * p < 0.05; versus CTRL HT29-dx: p < 0.005.
Gelsomino et al. Molecular Cancer 2013, 12:137 Page 7 of 20
http://www.molecular-cancer.com/content/12/1/137the intracellular doxorubicin retention (Figure 6A) and
restored its cytotoxicity in HT29-dx cells (Figure 6B).
Anthracyclines are amongst the few anticancer drugs
able to kill cancer cells by exerting direct cytotoxicity
on tumor cell and by inducing an immunogenic cell
death. This type of cell death is characterized by the
extracellular release of ATP and HMGB1, by the surface
translocation of calreticulin, and by the subsequent
phagocytosis of tumor cells by dendritic cells (DCs)
[42,43]. While doxorubicin elicited all these events
in HT29 cells, it was ineffective in HT29-dx cells
(Additional file 4A-B; Figure 6C-D; Table 6). EPA and
DHA, which did not further enhance the effects of doxo-
rubicin in chemosensitive cells, restored the doxorubicin-mediated release of extracellular ATP (Additional file
4A) and HMGB1 (Additional file 4B), the translocation
of calreticulin on cell surface (Figure 6C; Table 6)
and the DC-mediated phagocytosis of HT29-dx cells
(Figure 6D), confirming that they fully restored the pro-
immunogenic effects of doxorubicin. Of note, neither
DHA nor EPA alone increased ATP and HMGB1 re-
lease, calreticulin translocation and cells phagocytosis
(Additional file 4A-B; Figure 6C-D; Table 6), suggest-
ing that they were not immune-activating agents per
se, but only enhancers of doxorubicin activity. Again,
AA was completely ineffective in restoring doxorubicin
cytotoxicity and pro-immunogenic effects in HT29-dx
cells (Additional file 4; Figure 6; Table 6).
Table 1 Fatty acids composition of whole HT29 cells
CTRL AA DHA EPA
C16:0 30.131 ± 2.328 28.882 ± 2.166 30.803 ± 2.728 29.952 ± 3.450
C16:1 10.990 ± 1.086 8.669 ± 0.877 9.091 ± 1.042 7.308 ± 1.693
C18:0 13.155 ± 0.842 12.327 ± 0.595 12.052 ± 1.093 13.176 ± 1.604
C18:1 29.677 ± 1.260 30.412 ± 1.259 29.317 ± 2.910 26.824 ± 2.418
C18:2 4.003 ± 0.547 2.753 ± 0.221 2.612 ± 0.322 2.681 ± 0.317
C18:3 ω-3 0.513 ± 0.143 1.125 ± 0.202* 0.565 ± 0.073 0.723 ± 0.112
C18:3 ω-6 0.416 ± 0.060 0.129 ± 0.020* 0.176 ± 0.038* 0.131 ± 0.240
C20:3 1.222 ± 0.176 0.814 ± 0.035 0.833 ± 0.060 0.791 ± 0.031
C20:4 (AA) 6.032 ± 1.164 11.394 ± 1.177** 3.687 ± 0.332* 3.594 ± 0.344*
C20:5 (EPA) 1.536 ± 0.337 1.071 ± 0.220 1.638 ± 0.097 11.570 ± 2.685**
C22:5 0.743 ± 0.126 0.706 ± 0.123 0.886 ± 0.101 1.561 ± 0.306**
C22:6 (DHA) 1.760 ± 0.380 1.716 ± 0.350 8.339 ± 2.375** 1.689 ± 0.300
SFAa 43.285 ± 2.860 41.209 ± 2.345 42.855 ± 3.196 43.128 ± 4.836
MUFAb 40.667 ± 1.579 39.081 ± 1.561 38.409 ± 3.640 34.132 ± 3.632
ω-6 8.990 ± 0.759 15.091 ± 1.196** 7.308 ± 0.629 7.197 ± 0.608
ω-3 4.553 ± 0.738 4.620 ± 0.643 11.429 ± 2.477** 15.543 ± 3.073**
ω-6/ω-3 2.386 ± 0.307 3.371 ± 0.295 0.748 ± 0.172** 0.513 ± 0.095**
Fold increasec 3.008 6.634 11.209
HT29 cells were left untreated (CTRL) or treated with AA, DHA, EPA (50 μM for 48 h).
aSFA: saturated fatty acids; bMUFA: mono-unsaturated fatty acids.
cFold increase: AA, DHA or EPA in treated cells versus AA, DHA or EPA in untreated cells, respectively.
Data are presented as percentage of total fatty acids, mean ± SE (n = 3). Significance versus CTRL: *p < 0.05; **p < 0.01.
Gelsomino et al. Molecular Cancer 2013, 12:137 Page 8 of 20
http://www.molecular-cancer.com/content/12/1/137The rescue of chemosensitivity was not limited to
doxorubicin: indeed, the IC50 of irinotecan, another
substrate of Pgp [44], was higher in HT29-dx cells than
in HT29 cells (Figure 7A). The drug effectively reduced
the proliferation of HT29 cells, not of HT29-dx cells
(Figure 7B). DHA and EPA lowered the IC50 of irinote-
can in HT29-dx cells to a value similar to HT29 cells
(Figure 7A). Moreover, they restored the antiproliferative
effect of irinotecan in drug-resistant cells (Figure 7B).
Discussion
In this work we investigated whether ω3PUFAs – DHA
and EPA – chemosensitize MDR colon cancer cells, by
modulating the endogenous synthesis of cholesterol and
the cholesterol amount in plasma membrane, two fac-
tors that affect ABC transporters activity and determine
a MDR phenotype [25,26,28,30].
PUFAs have been reported to induce apoptosis in HT29
cells at concentrations higher than 200 μM after 24 h [15].
They are cytotoxic in colon cancer cells at 50 μM for pro-
longed periods (e.g. 6 days) [45], but do not reduce cell sur-
vival after 72 h [46]. Since we used ω3PUFAs and ω6PUFA
at 50 μM for 24 h, it is likely that we did not detect any
toxicity because of the short incubation time. Interestingly,
chemosensitive and chemoresistant cells displayed equal
sensitivity to the toxic effects of the highest concentrations
of PUFAs, suggesting that the MDR phenotype is notimportant for the PUFAs’ cytotoxicity. The similar toxicity
profile observed in HT29 and HT29-dx cells might also
suggest that PUFAs are not effluxed by the ABC trans-
porters present in HT29-dx cells.
Within cells, protein-bound fatty acids may reach con-
centrations up to 100 μM [15,47]. In order to work at a
non-toxic and physiological-like concentration of PUFAs,
we used ω3PUFAs and ω6PUFA at 50 μM in all the func-
tional assays.
AA significantly reduced the de novo synthesis of chol-
esterol only at a cytotoxic concentration (200 μM), sug-
gesting that such decrease was a non-specific effect.
50 μM DHA and EPA did not reduce the cholesterol syn-
thesis in chemosensitive HT29 cells, but significantly de-
creased it in chemoresistant HT29-dx cells. Since the
basal rate of cholesterol synthesis was higher in HT29-dx
cells than in HT29 cells, it is not surprising that the effect
of cholesterol-lowering agents – such as DHA and EPA –
was more evident in MDR cells. On the other hand, the
different effects exerted by ω3PUFAs in chemosensitive
and chemoresistant cells may be indicative of different
regulation mechanisms in cholesterol synthesis. HT29-dx
cells had higher activity and expression of HMGCoAR
mRNA and protein, accompanied by higher nuclear levels
of the transcriptional activator SREBP-2. SREBP-2 is up-
regulated by intracellular sterols and by the transcription
factor hypoxia inducible factor-1α (HIF-1α) [48], which is
Table 2 Fatty acids composition of whole HT29-dx cells
CTRL AA DHA EPA
C16:0 28.821 ± 2.333 28.352 ± 2.367 30.020 ± 3.349 29.630 ± 2.872
C16:1 10.532 ± 0.945 9.955 ± 1.003 9.027 ± 0.986 9.652 ± 0.905
C18:0 12.386 ± 1.082 11.401 ± 1.731 12.870 ± 2.455 12.229 ± 1.465
C18:1 30.878 ± 1.510 31.793 ± 2.214 30.288 ± 3.019 31.674 ± 2.552
C18:2 4.266 ± 0.792 2.563 ± 0.239 2.182 ± 0.368 3.025 ± 0.184
C18:3 ω-3 0.438 ± 0.068 0.955 ± 0.165** 0.514 ± 0.094 0.659 ± 0.036*
C18:3 ω-6 0.113 ± 0.011§ 0.111 ± 0.013 0.147 ± 0.038 0.107 ± 0.009
C20:3 1.181 ± 0.209 0.828 ± 0.027 0.874 ± 0.107 0.895 ± 0.080
C20:4 (AA) 6.571 ± 1.563 9.813 ± 0.560* 3.182 ± 0.590* 3.694 ± 0.431*
C20:5 (EPA) 1.707 ± 0.425 0.812 ± 0.060 1.477 ± 0.227 5.852 ± 0.677**
C22:5 0.875 ± 0.080 0.823 ± 0.102 0.835 ± 0.166 1.101 ± 0.106
C22:6 (DHA) 2.280 ± 0.467 1.594 ± 0.274 8.345 ± 2.915* 1.481 ± 0.350
SFAa 41.208 ± 2.757 40.753 ± 3.507 42.890 ± 5.505 41.860 ± 4.067
MUFAb 41.410 ± 2.336 41.748 ± 3.196 39.555 ± 3.886 41.326 ± 3.443
ω-6 12.083 ± 2.310 13.315 ± 0.539 6.385 ± 0.735* 7.721 ± 0.309*
ω-3 5.300 ± 0.904 4.184 ± 0.315 11.171 ± 2.988* 9.094 ± 0.697**
ω-6/ω-3 2.271 ± 0.198 3.208 ± 0.129** 0.679 ± 0.162** 0.863 ± 0.070**§
Fold increasec 2.782 5.862 7.028
HT29-dx cells were left untreated (CTRL) or treated with AA, DHA, EPA (50 μM for 48 h).
aSFA: saturated fatty acids; bMUFA: mono-unsaturated fatty acids.
cFold increase: AA, DHA or EPA in treated cells versus AA, DHA or EPA in untreated cells, respectively.
Data are presented as percentage of total fatty acids, mean ± SE (n = 3). Significance versus CTRL: *p < 0.05; **p < 0.01; versus the corresponding treatment in HT29
cells: §p < 0.05.
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conditions, but undetectable in HT29 cells [26]. The in-
creased activation of HIF-1α/SREBP-2 axis may explain
why HT29-dx cells have higher levels of HMGCoAR and
HMGCoAS mRNA, despite the higher levels of cholesterol
[25,26]. It is unlikely however that ω3PUFAs interfere with
this axis in HT29-dx cells: they indeed reduced HMGCoAR
activity and protein in chemoresistant cells, but did not de-
crease the nuclear translocation of SREBP-2 and the tran-
scription of HMGCoAR gene. Our data are partially in
contrast with previous works showing that DHA activated
SREBP-2 in SW620 colon cancer cells [23,24], without
changing however the transcription of HMGCoAR [23].
As far as we know, these works were performed on colon
cancer cells without a MDR phenotype; this may explain
the different behavior of DHA in SW620 cells and in che-
moresistant HT29-dx cells. Also in our hands DHA and
EPA did not produce any changes in chemosensitive
HT29 cells, which maintained lower HMGCoAR activity
and expression, and lower nuclear SREBP-2 compared
with HT29-dx cells.
Since DHA and EPA only reduced the amount of
HMGCoAR protein, without changing the HMGCoAR
mRNA or the enzyme phosphorylation, we next won-
dered whether ω3PUFAs modulated HMGCoAR degrad-
ation via the ubiquitin/proteasome system. Interestingly,MDR cells showed a lower level of enzyme ubiquitination
than chemosensitive cells, a situation that may explain the
increased basal amount of HMGCoAR protein. In both cell
lines, the proteasome inhibitor MG-132 further increased
the amount of ubiquitinated HMGCoAR, suggesting that
the ubiquitination was followed by proteasomal degrad-
ation. Of note, whereas AA did not affect the rate of ubi-
quitination, DHA and EPA increased the ubiquitination of
HMGCoAR in HT29-dx cells but not in HT29 cells.
When we analyzed the ubiquitination of HMGCoAR
in microsomal fraction, we found that the activity of the
ERAD system was significantly lower in MDR cells;
DHA and EPA increased ERAD activity to the same
levels of HT29 cells. In order to investigate the putative
target of ω3PUFAs, we first analyzed the expression of
Insig-1 and -2, which cooperate with the ER-associated
ubiquitin E3 ligases gp78 and Trc8 in the degradation of
HMGCoAR [39]. We did not detect any difference between
HT29 and HT29-dx cells, in the absence or presence of
AA, DHA and EPA, except for Trc8. This E3 ligase was
more expressed in HT29 cells than in HT29-dx cells: such
difference may explain the differential expression and deg-
radation of HMGCoAR between chemosensitive and che-
moresistant cells. Since neither DHA nor EPA changed the
expression of Trc8 and gp78, but they both increased
the ubiquitination of HMGCoAR, we hypothesized that
Table 3 Detergent resistant membrane (DRM) fatty acids composition of HT29 cells
CTRL AA DHA EPA
C16:0 35.973 ± 2.332 31.712 ± 1.344 31.684 ± 1.527 31.238 ± 2.09
C16:1 6.470 ± 1.522 8.098 ± 0.457 6.761 ± 1.409 9.479 ± 0.789
C18:0 14.923 ± 0.789 15.291 ± 0.352 16.787 ± 1.179 14.685 ± 0.971
C18:1 32.203 ± 1.068 30.241 ± 2.900 32.918 ± 2.472 30.065 ± 2.061
C18:2 3.184 ± 0.283 3.252 ± 0.895 2.871 ± 0.281 4.048 ± 1.115
C18:3 ω-3 0.352 ± 0.035 0.610 ± 0.150 0.389 ± 0.015 0.322 ± 0.084
C18:3 ω-6 0.521 ± 0.154 0.326 ± 0.059 0.389 ± 0.138 2.567 ± 1.893
C20:3 0.835 ± 0.160 0.308 ± 0.018 0.690 ± 0.022 0.581 ± 0.085
C20:4 (AA) 3.183 ± 0.477 8.455 ± 1.782** 3.303 ± 0.159 3.466 ± 0.428
C20:5 (EPA) 0.888 ± 0.178 0.589 ± 0.036 1.260 ± 0.353 1.827 ± 0.304*
C22:5 0.394 ± 0.066 0.590 ± 0.133 0.388 ± 0.101 0.565 ± 0.117
C22:6 (DHA) 1.077 ± 0.157 1.069 ± 0.082 2.553 ± 0.494** 1.158 ± 0.178
SFAa 50.895 ± 2.810 47.003 ± 1.387 48.471 ± 1.743 45.923 ± 2.935
MUFAb 38.673 ± 2.231 38.339 ± 3.201 39.679 ± 2.388 39.544 ± 2.518
ω-6 7.202 ± 0.862 12.650 ± 2.766* 6.863 ± 0.338 8.095 ± 1.397
ω-3 2.708 ± 0.311 2.711 ± 0.193 4.591 ± 0.732* 3.872 ± 0.358*
ω-6/ω-3 2.735 ± 0.234 4.576 ± 0.579** 1.577 ± 0.183** 2.122 ± 0.374
Fold increasec 2.403 2.116 2.199
HT29 cells were left untreated (CTRL) or treated with AA, DHA, EPA (50 μM for 48 h).
aSFA: saturated fatty acids; bMUFA: mono-unsaturated fatty acids.
cFold increase: AA, DHA or EPA in treated cells versus AA, DHA or EPA in untreated cells, respectively.
Data are presented as percentage of total fatty acids, mean ± SE (n = 4). Significance versus CTRL: *p < 0.05; **p < 0.01.
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firm this hypothesis, we set up a cell-free system, contain-
ing the human recombinant HMGCoAR protein, the E2
ubiquitin conjugating enzyme Ube2g2, which mediates the
degradation of several ER-associated proteins [49] includ-
ing HMGCoAR [40], and the recombinant gp78 or Trc8
proteins. DHA and EPA dose-dependently increased the
ubiquitination of HMGCoAR by activating the Ube2g2-
Trc8 system. Since Trc8 was more expressed in HT29
cells, where DHA and EPA did not increase the ubiquitina-
tion of HMGCoAR, we may speculate that Trc8 works at
its maximal rate in chemosensitive cells and cannot be
further activated by ω3PUFAs. By contrast, in HT29-dx
cells, where the amount of Trc8 was lower, the activating
effect of DHA and EPA became more evident. To our
knowledge, this is the first work reporting that ω3PUFAs
activate the E3 ligase Trc8. This observation also provides
mechanistic insights to explain previous works, reporting
that DHA increases the activity of ERAD system [23,24],
and the proteasomal degradation of specific proteins in
colon cancer [50]. Contrarily to DHA and EPA, AA had
no effect on Trc8, in keeping with its inefficacy in redu-
cing HMGCoAR and cholesterol synthesis. ω3PUFAs
and ω6PUFAs have different conformation and steric
hindrance; these factors can determine the selective in-
teractions with target proteins and the specificity of
their effects.A striking consequence of down-regulating cholesterol
synthesis in HT29-dx cells is the reduction of the choles-
terol amount in DRMs, which we extracted as described
[51,52]. It has been reported that DRMs contain about
40% of Pgp in drug-resistant HT29 cells [53]. Pgp, MRP1
and BCRP associated with DRMs are active and the pecu-
liar physicochemical properties of DRM domains – such
as the presence of cholesterol – preserve the transporters
activity [29,30,53,54]. The depletion of cholesterol from
DRMs indeed induces the shift of Pgp into soluble cell
fractions and the decrease of its activity [54]. This observa-
tion is in keeping with the decrease of surface- and DRM-
associated Pgp that we observed in HT29-dx cells treated
with EPA and DHA. The decrease of surface Pgp was not
accompanied by a reduced amount of Pgp in whole cell ly-
sates, suggesting that ω3PUFAs do not modulate the ex-
pression of Pgp, but only its intracellular distribution. To
our knowledge, the shift of MRP1 from DRMs into cytosol
following cholesterol depletion has not been described yet.
In HT29-dx cells, the surface level of MRP1 was also de-
creased by ω3PUFAs, suggesting that the localization of
this transporter may be sensitive as well to the amount of
cholesterol present in the plasma-membrane.
Beside lowering the amount of cholesterol, PUFAs were
effectively incorporated in whole cells and DRMs of HT29
and HT29-dx cells even if with different efficiency. Recent
works performed on reconstructed membranes and B
Table 4 Detergent resistant membrane (DRM) fatty acids composition of HT29-dx cells
CTRL AA DHA EPA
C16:0 33.091 ± 2.128 31.588 ± 1.305 32.446 ± 2.793 35.242 ± 1.836
C16:1 9.598 ± 0.716 9.155 ± 0.742 7.628 ± 2.111 9.443 ± 1.181
C18:0 14.605 ± 0.786 14.957 ± 0.709 16.538 ± 1.964 17.281 ± 0.933
C18:1 31.885 ± 1.922 30.603 ± 1.864 29.766 ± 2.366 30.369 ± 2.772
C18:2 3.511 ± 0.512 3.059 ± 0.934 3.107 ± 0.770 2.950 ± 0.340
C18:3 ω-3 0.351 ± 0.028 0.630 ± 0.052* 0.460 ± 0.011§§ 0.480 ± 0.057
C18:3 ω-6 0.480 ± 0.160 0.540 ± 0.183 0.455 ± 0.156 0.435 ± 0.226
C20:3 0.876 ± 0.059 0.700 ± 0.055 0.692 ± 0.032 0.654 ± 0.059
C20:4 (AA) 2.978 ± 0.266 7.599 ± 0.421** 3.093 ± 0.403 2.829 ± 0.395
C20:5 (EPA) 0.711 ± 0.053 0.717 ± 0.396 1.113 ± 0.214 3.498 ± 1.205**
C22:5 0.595 ± 0.141 0.507 ± 0.089 1.011 ± 0.619 0.481 ± 0.201
C22:6 (DHA) 1.320 ± 0.113 1.365 ± 0.113 4.500 ± 1.286** 1.258 ± 0.104
SFAa 47.696 ± 2.853 46.545 ± 1.903 48.984 ± 4.545 48.203 ± 5.614
MUFAb 41.483 ± 2.452 39.759 ± 2.546 37.394 ± 3.993 39.812 ± 3.942
ω-6 7.364 ± 0.609 10.403 ± 0.498* 6.891 ± 0.643 6.433 ± 0.401
ω-3 2.977 ± 0.266 3.218 ± 0.270 7.490 ± 1.974* 5.878 ± 1.461*
ω-6/ω-3 2.680 ± 0.160 3.141 ± 0.309 1.055 ± 0.287* 1.312 ± 0.378
Fold increasec 2.758 3.024 4.821
HT29-dx cells were left untreated (CTRL) or treated with AA, DHA, EPA (50 μM for 48 h).
aSFA: saturated fatty acids; bMUFA: mono-unsaturated fatty acids.
cFold increase: AA, DHA or EPA in treated cells versus AA, DHA or EPA in untreated cells, respectively.
Data are presented as percentage of total fatty acids, mean ± SE (n = 4). Significance versus CTRL: *p < 0.05; **p < 0.01; versus the corresponding treatment in HT29
cells: §§ p < 0.01.
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compared to EPA in whole cell lipids, in detergent-soluble
membranes and DRMs [55-57]. In HT29 cells, whereas
EPA and DHA were inserted at a similar extent in DRMs,
EPA was more greatly incorporated than DHA in whole
cell lipids. Such discrepancy with the situation observed in
B lymphocytes may be due to different protocols of treat-
ment and different metabolism of ω3PUFAs in the two cell
types [46]. For instance, after 15 hours of treatment, an
higher increase of DPA, a metabolite derived from EPA,
was observed in B lymphocytes [56]. Interestingly, theTable 5 Median and mean fluorescence intensity (MFI) of surf
Pgp Pgp M
Sample Median MFI Me
HT29 CTRL 8.24 ± 0.59 7.21 ± 0.11 5.15
HT29 AA 10.02 ± 2.25 8.58 ± 1.11 6.35
HT29 DHA 14.93 ± 2.02 8.74 ± 0.92 5.49
HT29 EPA 11.73 ± 1.01 10.09 ± 0.98 6.00
HT29-dx CTRL 34.84 ± 3.66* 31.06 ± 3.52* 34.01
HT29-dx AA 48.83 ± 4.72* 43.32 ± 4.98* 44.04
HT29-dx DHA 6.41 ± 0.52° 5.83 ± 0.41° 3.38
HT29-dx EPA 8.26 ± 0.51° 7.50 ± 0.21° 3.31
HT29 and HT29-dx cells were left untreated (CTRL) or treated with AA, DHA, EPA (50
Data were calculated with the Cell Quest software and are presented as mean ± SDsum of EPA and DPA incorporated in B lymphocyte mem-
branes [56] is in the same range of EPA incorporation
measured in HT29 and HT29-dx cells, wherein EPA is
poorly metabolized into DPA. This is not surprising, be-
cause different cell types have different rate of uptake,
metabolism and incorporation of ω3PUFAs [46]. It is
conceivable that the enzymatic activity of the elongase
which metabolizes EPA into DPA is low in our cell
lines, making the availability of EPA and its conse-
quent incorporation in cell membranes higher than in
other cell models.ace Pgp, MRP1 and BCRP in HT29 and HT29-dx cells
RP1 MRP1 BCRP BCRP
dian MFI Median MFI
± 0.43 4.61 ± 0.41 5.37 ± 0.25 4.71 ± 0.26
± 0.54 5.52 ± 0.36 6.80 ± 0.21 5.62 ± 0.37
± 0.29 5.25 ± 0.44 7.12 ± 0.47 6.49 ± 0.36
± 0.47 6.55 ± 0.34 6.15 ± 0.29 5.57 ± 0.19
± 2.15* 32.20 ± 1.08* 5.15 ± 0.23 4.96 ± 0.23
± 5.53* 41.05 ± 5.11* 7.74 ± 0.83 7.23 ± 0.41
± 0.41° 3.16 ± 0.37° 7.69 ± 0.79 7.23 ± 0.59
± 0.24° 2.89 ± 0.13° 8.17 ± 0.89 7.64 ± 0.48
μM for 48 h).
(n = 3). Versus CTRL HT29: *p < 0.002; versus CTRL HT29-dx: ° p < 0.001.
Figure 6 ω3PUFAs restore doxorubicin cytotoxicity in chemoresistant colon cancer cells. HT29 and HT29-dx cells were incubated for 48 h in
the absence (CTRL) or in the presence of 50 μM arachidonic acid (AA), docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA). 5 μM doxorubicin
(DOX) was added for 24 h, alone or during the last 24 h of incubation with fatty acids. Cycloheximide (4 μM for 24 h, CHX) was chosen as positive
control of cytotoxicity in both chemosensitive and chemoresistant cells. (A) The intracellular accumulation of doxorubicin was measured fluorimetrically
in duplicate. Data are presented as means ± SD (n = 3). Versus CTRL HT29: * p < 0.005; versus CTRL HT29-dx: ° p < 0.005. (B) Cells were stained with
Neutral Red solution and the absorbance of viable cells was measured in triplicate spectrophotometrically. Data are presented as means ± SD (n = 4).
Versus respective CTRL: * p < 0.002; versus DOX alone: ° p < 0.005. (C) Surface levels of calreticulin were measured in non-permeabilized cells by flow
cytometry. The figures shown here are representative of three similar experiments, performed in triplicate. (D) The phagocytosis rate by DCs was
evaluated in duplicate by flow cytometry. Data are presented as means ± SD (n = 4). Versus respective CTRL: * p < 0.05; versus DOX alone: p < 0.005.
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fies the DRMs organization, producing DRMs disassembly
and cholesterol displacement, inducing lateral phase sep-
aration into PUFA-rich/sterol-poor microdomains and
impairing the activity of many DRM-associated proteins
[34,36]. Pgp is one of these proteins, since its activity is
significantly reduced when the lipid environment of DRMs
is altered [58]. Together with the effects on cholesterol
synthesis, the incorporation of EPA and DHA in DRM
phospholipids is a second mechanisms by which ω3PUFAs
decrease the levels of Pgp and MRP1 in HT29-dx cells.
According to its structure, BCRP is less hydrophobic
than Pgp and MRP1 [27]. We cannot exclude that – differ-
ently from what we observed for Pgp and MRP1 – the en-
richment of ω3PUFAs and ω6PUFAs may favor the
retention of BCRP in DRMs compartment. In particular
the enrichment of DHA seemed the most suitable condi-
tion to increase BCRP levels in DRMs, in both HT29 andHT29-dx cells. Since the first-line drugs used in the treat-
ment of colon cancer (e.g. irinotecan, oxaliplatin, 5-
fluorouracil) are not substrates of BCRP, we do not believe
that the increase of BCRP may negatively affect the out-
come of patients subjected to the standard chemothera-
peutic regimen for colon cancer.
By contrast, in consequence of the decreased surface
levels of Pgp and MRP1, DHA and EPA overcame che-
moresistance to doxorubicin, a substrate of these two trans-
porters [27], and to irinotecan, a substrate of Pgp [44]. A
similar effect was produced by DHA and EPA in the Pgp-
overexpressing Caco-2 cells treated with paclitaxel [59].
DHA and EPA fully restored both the direct cytotoxicity
and the “indirect” pro-immunogenic toxicity of doxorubi-
cin, i.e. they decreased the cell viability, and increased the
release of ATP and HMGB1, the translocation of calreticu-
lin and the phagocytosis. Calreticulin expression is usually
associated with good prognosis in patients with advanced-
Table 6 Median and mean fluorescence intensity (MFI) of
surface calreticulin (CRT) in HT29 and HT29-dx cells
CRT CRT
Sample Median MFI
HT29 CTRL 4.96 ± 0.17 4.29 ± 0.32
HT29 DOX 57.59 ± 4.87* 53.28 ± 6.25*
HT29 AA 8.50 ± 1.69 7.37 ± 0.96
HT29 DHA 9.51 ± 2.14 7.57 ± 0.84
HT29 EPA 10.84 ± 2.39 8.74 ± 1.28
HT29 AA + DOX 65.44 ± 4.91* 67.17 ± 6.32*
HT29 DHA + DOX 70.40 ± 4.85* 58.82 ± 4.82*
HT29 EPA + DOX 68.16 ± 5.13* 59.35 ± 3.31*
HT29-dx CTRL 8.99 ± 1.89 8.51 ± 0.27
HT29-dx DOX 10.08 ± 2.78 10.09 ± 0.31
HT29-dx AA 11.41 ± 2.49 9.06 ± 0.97
HT29-dx DHA 10.85 ± 2.11 8.66 ± 0.41
HT29-dx EPA 6.77 ± 0.82 6.55 ± 0.53
HT29-dx AA + DOX 17.68 ± 5.15 14.72 ± 4.66
HT29-dx DHA + DOX 56.74 ± 4.60*° 46.56 ± 2.64*°
HT29-dx EPA + DOX 56.25 ± 5.21*° 44.11 ± 3.61*°
HT29 and HT29-dx cells were left untreated (CTRL) or treated with AA, DHA,
EPA (50 μM for 48 h).
Data were calculated with the Cell Quest software and are presented as mean ±
SD (n = 3). Versus CTRL HT29: *p < 0.001; HT29-dx DHA + DOX/EPA + DOX versus
HT29-dx DOX: ° p < 0.002.
Figure 7 ω3PUFAs restore the anti-proliferative effects of
irinotecan in chemoresistant colon cancer cells. HT29 and
HT29-dx cells were incubated for 48 h in the absence (CTRL) or
presence of 50 μM docosahexaenoic acid (DHA) or eicosapentaenoic
acid (EPA). (A) Irinotecan (CPT11) was added at increasing concentrations
in the last 24 h. Cells were stained with Neutral Red solution and the
absorbance of viable cells was measured in triplicate
spectrophotometrically. Data are presented as means ± SD (n = 4).
Versus respective CTRL: * p < 0.001; versus CPT11 alone: ° p <
0.005. (B) 10,000 HT29 and HT29-dx cells were seeded in 96-wells
plates. After 8 h, the medium was replaced with fresh medium
(CTRL), medium containing 50 μM docosahexaenoic acid (DHA),
50 μM eicosapentaenoic acid (EPA) or 1 μM irinotecan (CPT11),
alone or in combination. Cell proliferation was monitored at 12,
24, 48, 72, 96 h by crystal violet staining. Measurements were
performed in triplicate and data are presented as means ± SD (n = 4).
Versus respective CTRL: * p < 0.01; versus CPT11 alone: ° p < 0.01.
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http://www.molecular-cancer.com/content/12/1/137stage colon cancer, and correlates with a proper antitumor
response of the host immune system [60]. We demon-
strated that the association of ω3PUFAs and doxorubicin
enhanced the exposure of calreticulin in colon chemoresis-
tant cells. Although doxorubicin is not currently used in
colon cancer therapy, our work suggests that the combin-
ation of ω3PUFAs and doxorubicin might be noteworthy of
further studies to set up effective chemo-immunotherapy
protocols in colon cancer, a disease in which immune-
based interventions are under clinical investigation [61,62].
Irinotecan is currently used in colon cancer treatment. Our
results, showing that DHA and EPA lowered the IC50 of
irinotecan and completely restored its anti-proliferative ef-
fects in HT29-dx cells, may have a translational potential in
clinical settings.
The chemosensitizing effect of DHA and EPA has been
already described in HT29 cells, where they enhance the
pro-apoptotic effects of irinotecan, oxaliplatin and 5-
fluorouracil [63]. Our study is the first describing the effi-
cacy of ω3PUFAs in chemoresistant colon cancer cells.
The mechanism that we propose for such chemosensitiza-
tion – i.e. the inhibition of ABC transporters activity –
might help to explain why a dietary supplementation with
ω3PUFAs improves the efficacy of irinotecan in mice bear-
ing colon cancer [64], the efficacy of anthracyclines in pa-
tients with breast cancer [65], the efficacy of cisplatin plusvinorelbine in patients with non small cell lung cancer
[66]. Moreover our work provides the biochemical mech-
anism explaining why vincristine, a substrate of Pgp and
MRP1, was less effluxed by drug-resistant human cervical
cancer KB-ChR-8-5 cells treated with ω3PUFAs [67].
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We describe here a new effect of ω3PUFAs, i.e. the
down-regulation of the endogenous cholesterol synthesis
by promoting HMGCoAR ubiquitination via Trc8 E3 lig-
ase. Such effect is particularly pronounced in cells with a
dysregulated cholesterol synthesis – i.e. with high de-
mand of cholesterol, high intracellular levels of choles-
terol, high amount of HMGCoAR – such as MDR cells.
The decreased amount of cholesterol and the increased
incorporation of ω3PUFAs in DRMs alter the physico-
chemical properties of these compartments that are es-
sential for the proper localization and activity of ABC
transporters. As a result of these events, ω3PUFAs over-
come drug resistance towards substrates of Pgp and
MRP1, and restore a proper tumor-immune system rec-
ognition in response to chemotherapy in MDR cells
(Additional file 5).
The effects of ω3PUFAs are likely not limited to colon
cancer cells, because the increased demand of choles-
terol is a typical feature of several types of chemoresis-
tant tumors [25,26].
A diet rich of saturated fatty acids increases, whereas a
diet rich of ω3PUFAs decreases the onset of colon can-
cer. Whereas the chemopreventing effects of ω3PUFAs
are well-documented in colon cancer [11-16], their ef-
fects as MDR-overcoming agents have not been reported
previously in this tumor. Compared with other chemo-
sensitizing agents affecting the synthesis of cholesterol –
e.g. statins, aminobisphosphonates – [25,26], ω3PUFAs
are safer and have less side-effects. Therefore, a dietetic
supplementation with ω3PUFAs may be regarded not
only as a useful chemopreventive strategy, but also as a
potential adjuvant approach in patients with colon can-
cers unresponsive to chemotherapy.
Methods
Chemicals
Fetal bovine serum (FBS) and culture medium were pur-
chased from Invitrogen Life Technologies (Carlsbad, CA).
Plasticware for cell cultures was from Falcon (Becton
Dickinson, Franklin Lakes, NJ). AA, DHA, EPA, doxorubi-
cin, irinotecan were from Sigma Chemical Co. (St. Louis,
MO). Stock solutions of PUFAs were dissolved in absolute
ethanol and added on cell cultures as a mixture PUFAs/
fatty acid free bovine serum albumin (BSA), with a 3:1
ratio. The amount of ethanol added in each dish never
exceeded 0.5% v/v. Control cells were treated with a
0.5% v/v solution of ethanol. Simvastatin and MG-132
were obtained from Calbiochem (San Diego, CA). Elec-
trophoresis reagents were from Bio-Rad Laboratories
(Hercules, CA). The protein content of cell monolayers
and lysates was assessed with the BCA kit from Sigma
Chemical Co. Unless otherwise specified, all the other
reagents were from Sigma.Cells
Human chemosensitive colon cancer HT29 cells were from
ATCC (Rockville, MD). The chemoresistant counterpart
(HT29-dx cells) line was generated by culturing parental
cells in the presence of increasing concentrations of doxo-
rubicin for 20 passages [41]. HT29-dx cells have higher
Pgp, MRP1 and BCRP than HT29 cells [68]; moreover,
compared to HT29 cells, HT29-dx cells have a higher IC50
for doxorubicin (25.51 ± 1.33 μM versus 2.74 ± 0.67 μM;
p < 0.01), irinotecan (0.91 ± 0.18 μM versus 0.05 ± 0.01 μM;
p < 0.001), oxaliplatin (98.75 ± 6.08 μM versus 4.75 ±
0.71 μM; p < 0.001), and 5-fluorouracil (8.35 ± 0.64 μM ver-
sus 1.06 ± 0.14 μM; p < 0.05), representing a reliable model
of MDR cells. For the present work, HT29-dx cells were
grown in medium containing 200 nM doxorubicin. Cell
cultures were maintained in RPMI-1640 medium supple-
mented with 10% v/v FBS, 1% v/v penicillin-streptomycin
and 1% v/v L-glutamine, in a humidified atmosphere at
37°C and 5% CO2. All the experiments with these cell
lines were approved by Bioethics Committee (“Comitato
di Bioetica d’Ateneo”) of the University of Torino, Italy.
De novo synthesis of cholesterol
Cells were labeled with 1 μCi/ml [3H]acetate (3600 mCi/
mmol; Amersham Bioscience, Piscataway, NJ) and the syn-
thesis of radiolabeled cholesterol was measured as de-
scribed [69]: after 24 h the cells were washed twice with
phosphate-buffered saline (PBS) and mechanically scraped
in 200 μl of PBS. 500 μl of methanol and 1 ml of hexane
were added to the cell suspension, which was stirred at
room temperature for 1 h and then centrifuged at 2,000 × g
for 5 min. The upper phase containing hexane was trans-
ferred into a new test tube, and the lower phase was sup-
plemented with 1 ml of hexane and stirred overnight. After
a 5 min centrifugation at 2,000 × g, the upper phase was
added to the previous one and the solvent was allowed to
evaporate at room temperature for 24 h. Cellular lipid ex-
tracts produced by this separation were re-suspended in
30 μl of chloroform and then subjected to thin layer chro-
matography (TLC), using a 1:1 (v/v) ether/hexane solution
as mobile phase. Each sample was spotted on pre-coated
LK6D Whatman silica gels (Merck, Darmstadt, Germany)
and allowed to run for 30 min. Solutions of 10 μg/ml chol-
esterol were used as standard. The silica gel plates were ex-
posed for 1 h to a iodine-saturated atmosphere, then the
migrated spots were cut out and their radioactivity was
measured by liquid scintillation, using a Tri-Carb Liquid
Scintillation Analyzer (PerkinElmer, Waltham, MA). The
results were expressed as fmol [3H]cholesterol/mg cell pro-
teins, according to the relative calibration curve.
Cells viability, cytotoxicity and proliferation assays
In viability assays, cells were seeded in 24-wells plates,
treated for 24 h with AA, DHA and EPA at 25, 50, 100,
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medium containing 70 μg/ml of Neutral Red solution
(Sigma). Cells were washed three times with PBS and
rinsed with stop buffer (32 mM trisodium citrate,
50% v/v methanol; pH 6). The absorbance at 540 nm
was read using a Synergy HT Multi-Detection Micro-
plate Reader (Bio-Tek, Winooski, VT). The absorbance
of untreated cells was considered as 100% viability; the
results were expressed as percentage of viable cells ver-
sus untreated cells.
The percentage of annexin-V-positive cells, consid-
ered as apoptotic cells, was measured as previously re-
ported [69]: cells were treated for 24 h with 50 μM AA,
DHA or EPA, washed twice with fresh PBS, detached
with 200 μl of Cell Dissociation Solution (Sigma) for
10 min at 37°C and re-suspended in 500 μl of binding
buffer (100 mM Hepes, 140 mM NaCl, 25 mM CaCl2,
pH 7.5). Each sample was incubated with 10 μM
Annexin V-fluorescein isothiocyanate (FITC) for 5 min
at room temperature and the fluorescence was recorded
using a FACSCalibur system (Becton Dickinson Biosci-
ences, San Jose, CA), with a 530 nm band pass filter.
For each analysis 10,000 events were collected and the
percentage of cells positive for Annexin V-FITC was
calculated by the Cell Quest software (Becton Dickinson
Biosciences).
The extracellular release of high-mobility group 1
box (HMGB1) protein was taken as index of necrotic
and immunogenic death, the extracellular release of
ATP was considered an index of immunogenic death.
To measure the extracellular release of HMGB1, 20 μl
of the cell culture medium were boiled, resolved by
SDS-PAGE and probed with an anti-HMGB1 antibody
(Sigma). Blots were pre-stained with Red Ponceau to
check the equal loading of proteins. The ATP release
was measured on 100 μl of the cell culture medium
with the ATP Bioluminescent Assay Kit (FL-AA, Sigma
Aldrich Co.), using a Synergy HT Multi-Detection
Microplate Reader. The results were expressed as
nmol ATP/mg protein, according to the titration curve
previously set.
In proliferation assays, 10,000 cells were seeded in
96-wells plates and treated with 1 μM irinotecan,
50 μM DHA, 50 μM EPA, alone or in co-incubation.
At 12, 24, 48, 72, 96 h, cells were fixed with 4% w/v
paraformaldehyde and stained with 0.5% w/v crystal
violet solution for 10 min at room temperature. The
plate was washed three times in water, then 100 μl of
0.1 mM sodium citrate in 50% v/v ethanol was added
to each well. The absorbance was read at 570 nm using
a Synergy HT Multi-Detection Microplate Reader.
The absorbance units were converted into number of
cells, according to a titration curve obtained with serial
cells dilutions.HMGCoAR activity
The activity of HMGCoAR was measured in microsomal
fractions as described previously [69]. The cells were
rinsed with the lysis buffer (10 mM Tris, 100 mM
NaCl, 20 mM KH2PO4, 30 mM EDTA, 1 mM EGTA,
250 mM sucrose, pH 7.5) supplemented with protease
inhibitor cocktail set III (100 mM AEBSF, 80 mM aproti-
nin, 5 mM bestatin, 1.5 mM E- 64, 2 mM leupeptin,1
mM pepstatin; Calbiochem), 1 mM Na3VO4, 1 mM NaF,
1 mM 4-(2-aminoethyl)benzenesulphonyl fluoride (PMSF),
10 mM aprotinin, 10 mM dithiothreitol (DTT). After sonic-
ation (2 bursts of 10 s; Labsonic sonicator, Sartorius Stedim
Biotech S.A., Aubagne Cedex, France), cell lysates were
centrifuged at 13,000 × g for 15 min at 4°C; the
supernatants were subjected to ultracentrifugation at
100,000 × g for 1 h at 4°C, using a Optima L-90 K Beckman
Coulter Ultracentrifuge (Beckman Coulter Inc, Fullerton,
CA) to collect the microsomal fraction, which was re-
suspended in 250 μl of lysis buffer and stored at - 80°C until
the use. 12.5 μg of microsomal protein extracts, re-
suspended in 25 μl, were supplemented with 10 mM DTT,
5 mM NADP and with a NADPH-generating system
(1.3 mM glucose 6-phosphate, 0.67 U/ml of glucose-6-
phosphate dehydrogenase, 33 mM MgCl2). The reaction
was started by adding 60 nCi [14C]HMG-CoA (50-62 mCi/
mmol, Amersham Bioscience). After a 20 min incubation
at 37°C the reaction was stopped with 25 μl of 10 N HCl.
The samples were stirred for 30 min at 37°C to enhance
the complete lactonization of mevalonic acid, centrifuged at
13,000 × g for 2 min and separated by TLC on silica gel
plates with hexane/acetone (1:1, v/v) as mobile phase. A
1 mM solution of purified mevalonolactone was used as
standard. The labeled product (14C-mevalonolactone) was
recovered from the TLC plates and quantified by liquid
scintillation. The results were expressed as nmol [14C]
HMGCoA/min/mg cell proteins, according to the relative
calibration curve.
Quantitative Real Time-PCR (qRT-PCR)
Total RNA was extracted and reverse-transcribed using
the QuantiTect Reverse Transcription Kit (Qiagen, Hilden,
Germany). RT-PCR was carried out with IQ™ SYBR Green
Supermix (Bio-Rad). The same cDNA preparation was
used for the quantitation of HMGCoAR, HMGCoAS
and actin, chosen as a housekeeping gene. The sequences





ATTTCC-3′. The relative quantitation of each sample
was performed by comparing each PCR product with
the housekeeping PCR product, using the Software
Gene Expression Quantitation (Bio-Rad).
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For total, phosphorylated or ubiquitinated HMGCoAR
Western blot analysis, 50 μg of microsomal proteins,
collected as reported above, were immunoprecipitated
with an anti-HMGCoAR antibody (Santa Cruz Biotech-
nology, Santa Cruz, CA), in the presence of 100 mM
DTT and 1 mM mevalonic acid. For total HMGCoAR,
the immunoprecipitated samples were separated by
SDS-PAGE, transferred to polyvinylidene fluoride mem-
brane sheets (Immobilon-P, Millipore, Bedford, MA) and
probed with an anti-HMGCoAR antibody, followed by
the peroxidase-conjugated secondary antibody (Bio-Rad).
To detect HMGCoAR phosphorylated on serine, blots
were incubated with a biotinylated anti-phosphoserine
antibody (Sigma), followed by a streptavidin/horseradish
peroxidase-conjugated polymer (Sigma). For ubiquiti-
nated HMGCoAR, blots were probed with an anti-
ubiquitin antibody (Enzo Life Science, Farmingdale, NY),
followed by the peroxidase-conjugated secondary anti-
body. The levels of calreticulin, detected by a specific
antibody (ABR Affinity Bioreagents, Thermo Scientific,
Waltham, MA), were measured to check to equal load-
ing of microsomal proteins. Blot proteins were detected
by enhanced chemiluminescence (PerkinElmer).
To analyze the expression of Insig-1, Insig-2, gp78/
AMFR, Trc8/RNF-139, 20 μg of the microsomal ex-
tracts were probed with the following antibodies: anti-
Insig-1 (Abcam, Cambridge, MA), anti-Insig-2 (Abcam),
anti-gp78/AMFR (GeneTex Inc., Irvine, CA), anti-Trc8/
RNF-139 (Abnova, Taipei City, Taiwan).
Whole cell lysates were used for the Western blot ana-
lysis of Pgp, MRP1, BCRP. Cells were lysed in Mg2+ Lysis/
Wash Buffer (125 mM Tris-HCl, 750 mM NaCl, 1% v/v
NP40, 10% v/v glycerol, 50 mM MgCl2, 5 mM EDTA,
25 mM NaF, 1 mM Na3VO4, 10 μg/ml leupeptin, 10 μg/ml
pepstatin, 10 μg/ml aprotinin, 1 mM PMSF, pH 7.5), soni-
cated and centrifuged at 13,000 × g for 10 min at 4°C.
30 μg cell lysates were subjected to Western blotting
with anti-Pgp (Calbiochem), anti-MRP1 (Abcam), anti-
BCRP (Santa Cruz Biotechnology Inc.), anti-tubulin
(Santa Cruz Biotechnology Inc.) antibodies. For DRMs
samples, 5 μg of proteins from DRM fractions (see
below) were probed in Western blot analysis with anti-
Pgp, anti-MRP1, anti-BCRP, anti-flotillin (Abcam) or
anti-clathrin heavy chain (Abcam) antibodies.
Nucleus-cytosol separation was performed by using
the Nuclear Extract kit (Active Motiv, La Hulpe,
Belgium). 10 μg of nuclear extracts were subjected to
Western blot analysis, using anti-SREBP-1, anti-SREBP-
2 or anti-proliferating cell nuclear antigen (PCNA) anti-
body (Santa Cruz Biotechnology Inc.).
The densitometric analysis of Western blots was
performed with the ImageJ software (http://rsb.info.nih.
gov/ij/). Results were expressed as arbitrary units,where ‘1 unit’ is the mean band density in untreated
cells.HMGCoAR ubiquitination assay
To measure the ubiquitination of HMGCoAR, micro-
somal compartments were isolated from cell as de-
scribed above. The ubiquitination assay was performed
using the E3Lite Customizable Ubiquitin Ligase kit (Life-
Sensors Inc., Malvern, PA): 100 μg of microsomal pro-
teins were diluted in 100 μl of ubiquitination assay
buffer (1 M Tris/HCl, 500 mM MgCl2, 10 mM DTT,
pH 8), and incubated for 30 min at 37°C, in the presence
of 5 nM E1 activating enzyme provided by the kit, 100
nM E2 conjugating enzyme Ube2g2 (LifeSensors Inc.),
200 μM ATP, 6 mM human recombinant ubiquitin. When
indicated, 1 μM AA, DHA or EPA were added. Samples
were washed twice with PBS-Tween 0.1% v/v containing
5% w/v BSA and immunoprecipitated with the anti-
HMGCoAR antibody. The immunoprecipitated samples
were then incubated with the biotinylated anti-ubiquitin
antibody of the kit, followed by the streptavidin/horserad-
ish peroxidase-conjugated polymer and enhanced chemi-
luminescence detection reagent. The chemiluminescent
signal was read using a Synergy HT Multi-Detection Mi-
croplate Reader. A blank was performed in the absence of
microsomal extracts and its luminescence was subtracted
from the luminescence of each sample. The results were
expressed as relative luminescence units (RLU)/mg of
microsomal proteins.
To measure the ubiquitination of HMGCoAR in cell-free
systems, 1 μg of human recombinant HMGCoAR (catalytic
domain, GST-fusion protein produced in E. coli, Sigma),
dissolved in 100 μl of ubiquitination assay buffer, was incu-
bated with 5 nM E1 activating enzyme provided by the
E3Lite Customizable Ubiquitin Ligase kit, 100 nM E2 con-
jugating enzyme Ube2g2, 200 μM ATP, 6 mM human re-
combinant ubiquitin, 1.5 μM human recombinant E3
ligases Trc8/RNF-139 (Abnova) or gp78/AMFR (Abnova).
AA, DHA or EPA were added at different concentrations.
Samples were maintained at 37°C for 30 min; the quantifi-
cation of ubiquitinated HMGCoAR was performed as re-
ported above. This assay was considered an index of the
activity of Trc8 and gp78 E3 ligases, respectively.Lipid composition analysis
Lipids were extracted according to [70] with three differ-
ent chloroform/methanol mixtures (1:1, 1:2 and 2:1, v/v)
and partitioned with water and with the theoretical upper
phase (chloroform/methanol/water, 47:48:1, v/v). The or-
ganic phase was dried and then suspended in chloroform/
methanol (2:1, v/v) for the analysis of total fatty acid and
cholesterol contents. Each solvent contained 50 μM 2,6-
bis(1,1-dimethylethyl)-4-methylphenol (BHT).
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chromatography. The methyl esters were obtained by reac-
tion with 3.33% (w/v) sodium methoxide in methanol and
injected into an Agilent Technologies (6850 series II) gas
chromatograph equipped with a flame ionization detector
and a capillary column (AT Silar) (length 30 m, film thick-
ness 0.25 μm). The carrier gas was helium, the injector
temperature was 250°C, the detector temperature was 275°
C, the oven temperature was set at 50°C for 20 min and
then increased to 200°C at 10°C min–1 for 20 min. A stand-
ard mixture containing all fatty acid methyl esters (Sigma)
was injected for calibration, and heptadecanoic acid methyl
ester (Sigma) was used as internal standard.
The cholesterol analysis was achieved by high-
pressure liquid chromatography HPLC (Jasco, Tokyo,
Japan) equipped with ELSD detector (Sedere, Alfortville
Cedex, France) and silica normal-phase LiChrospher Si 60
column (LiChroCART 250-4; Merck, Darmstadt, Germany).
The cholesterol amount was related to the cell protein
content.
Isolation of Detergent Resistant Membranes (DRMs)
The extraction of DRMs was performed as reported previ-
ously [51]. This is a common biochemical method to
analyze the domain organization of membranes. Although
detergent treatment disrupts most lipid-lipid interactions,
a minor fraction of cell membranes is preserved and can
be isolated as DRMs. DRMs represent no-native “lipid
rafts” but they are a useful tool to study changes in com-
position related to biochemical, physiological or patho-
logical raft associated events [71].
Cells were harvested by scraping in PBS containing
0.4 mM Na3VO4, then centrifuged at 1,300 × g for
2 min, suspended in 1.4 ml lysis buffer (1% Triton X-
100, 10 mM Tris buffer, pH 7.5, 150 mM NaCl, 5 mM
EDTA, 1 mM Na3VO4, 1 mM PMSF, 75 mU/ml aproti-
nin), maintained in ice for 20 min, and finally treated with
Dounce homogenizer (10 strokes, tight). The DRMs were
purified on sucrose gradient as previously described [35].
After centrifugation 11 fractions were collected; to con-
firm the purity of DRMs, the content of cholesterol, phos-
pholipids, gangliosides, clathrin heavy chain and flotillin-1
was determined in each fraction by TLC and Western blot
(data not shown). DRMs protein content, fatty acid com-
position and cholesterol content were analyzed as de-
scribed above.
Flow cytometry analysis
Cells were washed twice with PBS, rinsed with 1 ml of
0.25% (w/v) PBS-BSA and centrifuged at 10,000 × g for
5 min. The pelleted cells were incubated for 45 min at
4°C with the anti-Pgp, anti-MRP1, anti-BCRP or anti-
calreticulin antibodies, then washed and incubated with
a secondary FITC-conjugated antibody for 30 min at 4°Cin the dark. After fixation in paraformaldehyde 2% v/v,
cells were re-suspended in 0.5 ml PBS-BSA and analyzed
using a FACS-Calibur system. For each analysis 100,000
events were collected. The percentage of viable (propi-
dium iodide-negative) fluorescent cells was calculated by
the Cell Quest software. Control experiments included in-
cubation with non immune isotypic antibodies followed
by the secondary antibody.
Intracellular doxorubicin accumulation
Intracellular doxorubicin content was detected with a fluo-
rimetric assay as reported [41]. Cells were incubated for
24 h in medium containing 5 μM doxorubicin, washed
twice with PBS, detached with trypsin/EDTA, centrifuged
for 30 s at 13,000 × g, re-suspended in 1 ml of a 1:1
mixture of ethanol/0.3 N HCl and sonicated. The protein
content of the cell lysates was measured and the amount of
intracellular doxorubicin was detected using a PerkinElmer
LS-5 spectrofluorimeter (PerkinElmer). Excitation and
emission wavelengths were 475 and 553 nm, respectively.
A blank was prepared in the absence of cells in each set of
experiments and its fluorescence was subtracted from the
one measured in each sample. The results were expressed
as nmol doxorubicin/mg cell proteins according to a pre-
viously prepared calibration curve.
Dendritic cell (DC) generation and in vitro
phagocytosis assay
The generation of DCs and their phagocytosis of colon
cancer cells were performed as described earlier [26]. DCs
were generated from peripheral blood samples obtained
from healthy donors kindly provided by the local Blood
Bank (Fondazione Strumia, Torino, Italy). Cells were har-
vested on day 6 and confirmed as immature DCs by
morphology and immunophenotype (data not shown).
HT29 and HT29-dx cells were green-stained with PKH2-
FITC (Sigma), washed twice and incubated with DCs at a
ratio of 1:1 for 18 h at 37°C. Co-cultures were then stained
for 20 min at 4°C with APC-conjugated HLA-DR antibody
(Miltenyi Biotec, Tetrow, Germany) to mark DCs. Two-
color flow cytometry was performed with FACS-Calibur
system and CellQuest software. At least 10,000 events were
accumulated specifically backgating on DC morphology
(region 1: FSC versus SSC). Tumor cell phagocytosis was
assessed as the percentage of double-stained (FITC plus
APC) cells. Tumor cells do not express significant amounts
of HLA-DR, and they were excluded from region 1 by
their morphology. In each set of experiments, a phago-
cytosis assay was performed by co-incubating DCs and
tumor cells at 4°C, instead of 37°C, and the percentage of
double-stained cells obtained after the incubation at 4°C
was subtracted from values observed at 37°C. The phago-
cytosis rate was expressed as “phagocytic index”, calculated
as reported in [42].
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Data are reported as mean ± SD of at least three independ-
ent experiments. Results were checked for normal distri-
bution and analyzed by a one-way analysis of variance
(ANOVA) followed by Dunnet’s t test. p < 0.05 was consid-
ered significant.Additional files
Additional file 1: Effects of ω3PUFAs on apoptosis and necrotic/
immunogenic death of colon cancer cells. HT29 and HT29-dx cells
were incubated for 24 h in the absence (CTRL) or presence of 50 μM
arachidonic acid (AA), docosahexaenoic acid (DHA), eicosapentaenoic
acid (EPA). Cycloheximide (4 μM for 24 h, CHX) was chosen as positive
control of cytotoxicity in both chemosensitive and chemoresistant cells;
doxorubicin (5 μM for 24 h, DOX) was chosen as positive control of
cytotoxicity in chemosensitive cells. A. Annexin V staining. The percentage
of cells positive for surface annexin V, taken as index of apoptosis, was
measured in duplicate by flow cytometry. Data are presented as means ±
SD (n = 3). Versus respective CTRL: * p < 0.001; DOX in HT29-dx versus DOX
in HT29: ° p < 0.001. B. Western blot analysis of extracellular HMGB1, taken as
index of necrotic/immunogenic death. Red Ponceau staining was used to
check the equal loading of proteins. The figure is representative of two
experiments with similar results. The band density ratio between HMGB1
and the Red Ponceau-positive bands was expressed as arbitrary units.
Versus CTRL HT29: * p < 0.002.
Additional file 2: Effects of ω3PUFAs on HMGCoAS transcription
and SREBPs nuclear translocation in colon cancer cells. HT29 and
HT29-dx cells were incubated for 24 h in the absence (CTRL) or
presence of 50 μM arachidonic acid (AA), docosahexaenoic acid (DHA),
eicosapentaenoic acid (EPA). A. Total RNA was extracted, reverse-transcribed
and subjected to qRT-PCR for HMGCoAS gene. Measurements were
performed in triplicate and data are presented as means ± SD (n = 3). Versus
CTRL HT29: * p < 0.05. B. Western blot detection of SREBP2 and SREBP1,
performed on nuclear extracts. Proliferating cell nuclear antigen (PCNA)
expression was used as a control of equal loading of nuclear proteins. The
figure is representative of three experiments with similar results. The band
density ratio between each protein and PCNA was expressed as
arbitrary units. Versus CTRL HT29: * p < 0.02.
Additional file 3: Effects of ω3PUFAs on Pgp, MRP1 and BCRP
expression in colon cancer cells. HT29 and HT29-dx cells were
incubated for 48 h in the absence (CTRL) or presence of 50 μM
arachidonic acid (AA), docosahexaenoic acid (DHA), eicosapentaenoic
acid (EPA). The expression of Pgp, MRP1 and BCRP was measured on
whole cell lysates by Western blotting. Tubulin expression was used as a
control of equal protein loading. The figure is representative of three
experiments with similar results. The band density ratio between each
protein and tubulin was expressed as arbitrary units. Versus CTRL HT29:
* p < 0.02.
Additional file 4: ω3PUFAs restore the pro-immunogenic death
induced by doxorubicin in chemoresistant colon cancer cells.
HT29 and HT29-dx cells were incubated for 48 h in the absence (CTRL)
or presence of 50 μM arachidonic acid (AA), docosahexaenoic acid (DHA),
eicosapentaenoic acid (EPA). 5 μM doxorubicin (DOX) was added for
24 h, alone or during the last 24 h of incubation with fatty acids.
Cycloheximide (4 μM for 24 h, CHX) was chosen as positive control of
cytotoxicity in both chemosensitive and chemoresistant cells. A. The
release of extracellular ATP was measured in triplicate by a chemiluminscent
assay. Data are presented as means ± SD (n = 4). Versus respective CTRL:
* p < 0.02; versus DOX alone: ° p < 0.01. D. Western blot analysis of
extracellular HMGB1, taken as index of necrosis and immunogenic death.
Red Ponceau staining was used to check the equal loading of protein. The
figure is representative of two experiments with similar results. The band
density ratio between HMGB1 and the Red Ponceau-positive bands was
expressed as arbitrary units. Versus CTRL HT29: * p < 0.002; versus CTRL
H29-dx: ° p < 0.002.Additional file 5: Chemo-immunosensitizing effects of ω3PUFAs in
chemoresistant colon cancer cells. A. MDR cells such as HT29-dx have
deficient activity of the Trc8 E3 ubiquitin ligase, higher expression and ac-
tivity of 3-hydroxy-3-methylglutaryl-coenzyme A reductase, higher
synthesis of cholesterol and higher levels of cholesterol in plasma-membrane.
This situation favours the activity of ATP binding cassette transporters such as
P-glycoprotein and limits the intracellular accumulation of specific
chemotherapeutic drugs like doxorubicin, which is not able to induce direct
cytotoxicity on tumor cell and to translocate calreticulin on cell surface, the
first step to induce cell phagocytosis by dendritic cells. B. Docosahexaenoic
acid and eicosapentaenoic acid restore the Trc8-mediated ubiquitnation of
3-hydroxy-3-methylglutaryl-coenzyme A reductase and its proteasomal
degradation, lower the cholesterol synthesis and the amount of cholesterol in
plasma-membrane and detergent resistant membranes. Moreover they are
well incorporated in whole cell membrane and detergent resistant
membranes, where they alter the physicochemical properties of the
lipid environment and reduce the amount of P-glycoprotein. As a result,
doxorubicin is more accumulated in MDR cells, exerts cytotoxic effects and
promotes the surface translocation of calreticulin, followed by the dendritic
cells-mediated phagocytosis. MDR: multidrug resistance; HMGCoAR:
3-hydroxy-3-methylglutaryl-coenzyme A reductase; Uq: ubiquitin; SREBP2:
sterol regulatory element binding protein-2, Pgp: P-glycoprotein; CRT:
calreticulin; d: doxorubicin; DHA: docosahexaenoic acid; EPA:
eicosapentaenoic acid.
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